Audentes Therapeutics Inc., of San Francisco, said it started dosing patients in ASPIRO, a phase I/II trial of gene therapy candidate AT-123 for the treatment of X-linked myotubular myopathy (XLMTM), a rare monogenic disease characterized by extreme muscle weakness, respiratory failure and early death, with an estimated 50 percent mortality rate by 18 months of age.